The 20 Best Multiple Myeloma Doctors Near Me in Columbia, MD

As an active participant in the medical community, Mohit Narang, M.D. has served as a primary investigator and research assistant on many trials. During Dr. Narang’s fellowship, he was honored with the invitation to attend the Masterclass in Clinical Oncology at Montecatini, Italy by the European School of Oncology. He holds professional memberships with the American Society of Clinical Oncology, American Society of Hematology, as well as the European Society of Medical Oncology. Learn more at marylandoncology.com. Dr. Narang is rated as an Elite provider by MediFind in the treatment of Multiple Myeloma. He is also highly rated in 43 other conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Agranulocytosis, Paget Disease of the Breast, Thrombocytopenia, and Bone Marrow Transplant. Dr. Narang is board certified in American Board Of Internal Medicine.

Carol Ann Huff, M.D., is an Associate Professor of Oncology and Medicine at the Johns Hopkins University School of Medicine and Medical Director for the Johns Hopkins Kimmel Cancer Center. After completing a Bachelor of Science in Zoology at Duke University in Durham, NC, Dr. Huff received her medical degree from Baylor College of Medicine in Houston. She completed her internship and residency in Internal Medicine at Johns Hopkins and was an Assistant Chief of Service in the Department of Medicine before completing her fellowship training in the Department of Oncology at Johns Hopkins University. Dr. Huff is a nationally-recognized expert in the treatment of multiple myeloma and amyloidosis and in the development of new biologically-based treatment strategies. She has sought to better understand the mechanisms for recurrence and the inability to cure these diseases. Through this research, the identification of a myeloma cancer stem cell has emerged, and efforts to target these cells through combination therapy in clinical trials are ongoing. In collaboration with Dr. William Matsui, Dr. Huff has identified a flow cytometric-based blood analysis for multiple myeloma patients that can be used to quantify the number of myeloma cancer stem cells and track how these cells respond to treatment. Their efforts have revealed that changes in the number of myeloma cancer stem cells can predict recurrence in myeloma patients before clinical evidence of recurrence is detectable. Using this blood analysis, as well as growth of these cells from bone marrow samples taken from patients with myeloma, they have begun studying therapeutic strategies to target these cells based on cell surface markers and enzymatic pathways that are important to the survival of myeloma stem cells. Dr. Huff is the recipient of multiple awards for clinical and teaching excellence including the Kimmel Cancer Center's Director’s Teaching Award in Oncology in both 2006 and 2012. During her medical school training, Dr. Huff was the recipient of a Howard Hughes Medical Institute-National Institutes of Health (NIH) fellowship. She has received grant support from the NIH, Multiple Myeloma Research Foundation, and Leukemia and Lymphoma Society. and LLS, and is the principal investigator of numerous investigator-initiated and industry- sponsored clinical trials. She is the author of numerous publications and book chapters not only on multiple myeloma and related disorders, but also on bone marrow transplantation and a range of topics related to internal medicine and oncology. Her current research efforts involve active collaboration with the preclinical laboratories in the development and testing phases of new therapeutic approaches, as well as a lead effort in the national African American Myeloma Consortium seeking to better understand genetic determinants of the disease. Dr. Huff is rated as an Elite provider by MediFind in the treatment of Multiple Myeloma. She is also highly rated in 6 other conditions, according to our data. Her clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, and Plasmacytoma. Dr. Huff is board certified in American Board Of Internal Medicine.

Andrew Mener, M.D. has experience treating a wide range of adult hematologic and oncologic disorders, with a particular interest in treating breast, lung, gastrointestinal and hematologic malignancies. He takes great pride in delivering personalized, compassionate care and strives to effectively explain complex treatment options to his patients. He strongly believes in the importance of treating each and every patient as an individual. Learn more at marylandoncology.com. Dr. Mener is rated as an Advanced provider by MediFind in the treatment of Multiple Myeloma. He is also highly rated in 48 other conditions, according to our data. His clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Iron Deficiency Anemia, and Severe Congenital Neutropenia. Dr. Mener is board certified in American Board Of Internal Medicine.

Edward Lee, M.D. was named one of Baltimore’s “Top Doc’s” by Baltimore Magazine in 2000 and 2002. After receiving additional training in Hematology and Medical Oncology at the University of Maryland in 1984, he remained on faculty until 1997. During his academic career, Dr. Lee was chairman of the training program for five years, started the Bone Marrow Transplant Program at the University of Maryland in 1993, and wrote 50 original articles on leukemia, lymphoma and related diseases. In 1997, Dr. Lee entered private practice as Chief of Hematology and Medical Oncology at Sinai Hospital. Practicing in Columbia since 2001, Dr. Lee treats patients with all forms of cancer, maintaining a particular interest in breast cancer, leukemia, and lymphomas. Learn more at marylandoncology.com. Dr. Lee is rated as an Advanced provider by MediFind in the treatment of Multiple Myeloma. He is also highly rated in 42 other conditions, according to our data. His clinical expertise encompasses Polycythemia Vera, Paget Disease of the Breast, Breast Cancer, and Primary Lymphoma of the Brain. Dr. Lee is board certified in American Board Of Internal Medicine.

Learn more at marylandoncology.com. Dr. Sastry is rated as an Advanced provider by MediFind in the treatment of Multiple Myeloma. She is also highly rated in 52 other conditions, according to our data. Her clinical expertise encompasses Paget Disease of the Breast, Breast Cancer, Iron Deficiency Anemia, and Childhood Iron Deficiency Anemia. Dr. Sastry is board certified in American Board Of Internal Medicine.

Ari Elman is an Oncologist practicing medicine in Columbia, Maryland. He has been practicing medicine for over 17 years. Dr. Elman is rated as a Distinguished provider by MediFind in the treatment of Multiple Myeloma. He is also highly rated in 34 other conditions, according to our data. His clinical expertise encompasses Pleuropulmonary Blastoma, Lung Cancer, Small Cell Lung Cancer (SCLC), and Multiple Myeloma.

Gayatri Nimmagadda is a Hematologist and a Hematologist Oncology provider practicing medicine in Columbia, Maryland. Dr. Nimmagadda is rated as an Experienced provider by MediFind in the treatment of Multiple Myeloma. She is also highly rated in 14 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Iron Deficiency Anemia, and Pleuropulmonary Blastoma. Dr. Nimmagadda is board certified in American Board Of Internal Medicine.

Ashraf Badros is an Oncologist practicing medicine in Baltimore, Maryland. Dr. Badros is rated as an Elite provider by MediFind in the treatment of Multiple Myeloma. He is also highly rated in 5 other conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Plasmacytoma, and Bone Marrow Transplant.

Djordje Atanackovic is a Hematologist practicing medicine in Baltimore, Maryland. Dr. Atanackovic is rated as an Elite provider by MediFind in the treatment of Multiple Myeloma. He is also highly rated in 13 other conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, T-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Mehmet Kocoglu is a Hematologist practicing medicine in Baltimore, Maryland. Dr. Kocoglu is rated as an Elite provider by MediFind in the treatment of Multiple Myeloma. He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Aaron Rapoport is a Hematologist practicing medicine in Baltimore, Maryland. Dr. Rapoport is rated as an Elite provider by MediFind in the treatment of Multiple Myeloma. He is also highly rated in 26 other conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Multiple Myeloma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Najeff Waseem is a Hematologist and a Hematologist Oncology provider practicing medicine in Columbia, Maryland. He has been practicing medicine for over 10 years. Dr. Waseem is rated as an Experienced provider by MediFind in the treatment of Multiple Myeloma. He is also highly rated in 9 other conditions, according to our data. His clinical expertise encompasses Thrombocytopenia, Chronic Familial Neutropenia, Agranulocytosis, and Triple-Negative Breast Cancer. Dr. Waseem is board certified in American Board Of Internal Medicine.

Arshia Soleimani is a Hematologist Oncology specialist and a Hospital Medicine provider practicing medicine in Columbia, Maryland. Dr. Soleimani is rated as an Experienced provider by MediFind in the treatment of Multiple Myeloma. Her clinical expertise encompasses Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Colorectal Cancer, and Lynch Syndrome. Dr. Soleimani is board certified in American Board Of Internal Medicine.

Dr. Philip Imus is an oncologist in the Baltimore area, caring for patients with hematologic malignancies. Dr. Imus received his undergraduate degree (cum laude) in English from Rice University. He earned his M.D. from Columbia University College of Physicians and Surgeons. He completed his residency in internal medicine at New York-Presbyterian/Weill Cornell Medical Center and performed a fellowship in oncology at Johns Hopkins. Dr. Imus is rated as a Distinguished provider by MediFind in the treatment of Multiple Myeloma. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration.

Christian Gocke is a Hematologist practicing medicine in Baltimore, Maryland. He has been practicing medicine for over 17 years. Dr. Gocke is rated as a Distinguished provider by MediFind in the treatment of Multiple Myeloma. He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Acute Myeloid Leukemia (AML), Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Gocke is board certified in American Board Of Internal Medicine.

Dr. Syed Abbas Ali is a medical oncology specialist in Baltimore, caring for patients with cancer. Dr. Ali earned his M.B.B.S. at The Aga Khan University. He completed his residency at the University of Arkansas for Medical Sciences and performed a fellowship in medical oncology at the National Institutes of Health. Dr. Ali is rated as a Distinguished provider by MediFind in the treatment of Multiple Myeloma. He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Aspiration, and Gastrostomy.

Karl Kasamon is a Hematologist practicing medicine in Columbia, Maryland. Dr. Kasamon is rated as an Experienced provider by MediFind in the treatment of Multiple Myeloma. His clinical expertise encompasses Iron Deficiency Anemia, Schnitzler Syndrome, Monoclonal Gammopathy of Undetermined Significance (MGUS), and RUNX1 Familial Platelet Disorder.

Richard F. Ambinder, M.D., Ph.D., currently serves as the James B. Murphy Professor of Oncology and the Director of the Division of Hematologic Malignancies at the Johns Hopkins Kimmel Cancer Center. He is program co-leader of the Hematologic Malignancies and Bone Marrow Transplantation Program and leads the AIDS Malignancy Consortium (AMC) site at Johns Hopkins and the AMC Translational Sciences Working Group nationally. Dr. Ambinder graduated from Harvard College with a Bachelor’s degree in biochemistry, after which he received his medical degree from the Johns Hopkins University School of Medicine before completing his residency at the Johns Hopkins Hospital. He also earned his Ph.D. in pharmacology from the Johns Hopkins University, and completed his oncology fellowship at Johns Hopkins. Within the clinic, Dr. Ambinder is active in the treatment of lymphoma and Kaposi’s sarcoma. Dr. Ambinder’s research is focused on exploring opportunities to prevent or treat cancer with viral infections. Virus-associated tumors are among the most common malignancies in certain populations and regions. For instance, Burkitt's lymphoma (EBV) and Kaposi's sarcoma (KSHV) are common in equatorial Africa, nasopharyngeal carcinoma (EBV) is common in southern Chinese populations or those with southern Chinese origins, and immunoblastic lymphomas (EBV) are common in immunocompromised patients (organ transplant recipients, AIDS patients, etc). Thus, Dr. Ambinder’s new approaches to prevention, diagnosis, and treatment stand to have a direct impact on the lives of cancer patients around the globe. Additionally, the study of how viruses can impact these tumors is important in creating model systems for the development of new approaches to cancer care. Currently, many immunotherapies target unidentified antigens, making the measurement of relevant immune responses problematic at best. However, in EBV-associated tumors the antigens are well defined, thus allowing the Ambinder lab to define the epitope-specific cellular immune responses. As a result of this breakthrough, interventions designed to alter immune response —whether they be vaccine based interventions, adoptive immunotherapy interventions, or pharmacologic interventions — may all be assessed in terms of relevant surrogate markers. Much in the same way the treatment of Hodgkin's lymphoma with radiotherapy and chemotherapy paved the way for the modern approach to cancer treatment more broadly, the treatment of EBV-associated tumors (including Hodgkin's lymphoma) may pave the way to the more generalized use of these modalities to treat a myriad of cancer types. Dr. Ambinder is rated as an Advanced provider by MediFind in the treatment of Multiple Myeloma. He is also highly rated in 23 other conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Tissue Biopsy, and Bone Marrow Aspiration. Dr. Ambinder is board certified in American Board Of Internal Medicine.

B.S., Massachusetts Institute of Technology M.D., University of Pennsylvania School of Medicine M.B.A., Carey School of Business at Johns Hopkins. Dr. Fuchs is rated as an Advanced provider by MediFind in the treatment of Multiple Myeloma. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Myelodysplastic Syndrome (MDS), Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML), and Bone Marrow Aspiration. Dr. Fuchs is board certified in American Board Of Internal Medicine.

Dr. DeZern is a Professor of Oncology and Medicine at The Johns Hopkins University School of Medicine. She is active in the Division of Hematology Malignancies, Leukemia Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. DeZern has expertise in aplastic anemia, myelodysplastic syndromes, paroxysmal nocturnal hemoglobinuria, acute myeloid leukemia, and bone marrow transplantation. Dr. DeZern received her medical degree at The Johns Hopkins University School of Medicine. She completed a residency in internal medicine at Johns Hopkins, followed by fellowships in medical oncology and hematology, as well as obtained a Masters in Clinical Investigations at the Bloomberg School of Public health. Dr. DeZern is a member of the American Society of Hematology, the American Society of Clinical Oncology, and the American Society for Transplantation and Cellular Therapy. Dr. DeZern’s principle research activities consist of designing and conducting clinical trials that test investigational new therapies and approaches in the treatment of bone marrow failure (aplastic anemia and myelodysplastic syndromes). She has specific expertise in the use of alternative donor bone marrow transplantation in patients with severe aplastic anemia and trials of novel therapeutics for patients with myelodysplastic syndromes. Additionally, she has taken a rigorous approach to the study of diagnostics and supportive case (such as transfusion practices) in these patient populations. She is or has been the Principal Investigator for a number of multicenter trials in collaboration with the MDS Clinical Research Consortium, the Eastern Co-operative Oncology Group (ECOG)-ACRIN and now the Bone Marrow Trials Clinical Trials Network (BMTCTN). She is the Study Chair for the multi-site BMTCTN study (CHAMP) investigating the role of haploidentical donor transplantation using post-transplantation cyclophosphamide in patients with relapsed several aplastic anemia. Dr. DeZern is the local PI as well as the Deputy Chair for The National MDS Study, a collaborative natural history study of the NHLBI and the NCI. As a clinical investigator with a focus on translation of novel treatments to the clinic, Dr. DeZern’s goal is to improve outcomes for patients with bone marrow failure at the bedside and in her research environment. Dr. Dezern is rated as an Advanced provider by MediFind in the treatment of Multiple Myeloma. She is also highly rated in 27 other conditions, according to our data. Her clinical expertise encompasses Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Dezern is board certified in American Board Of Internal Medicine.